Key Points
- CEO Martine Rothblatt sold 4,000 shares of United Therapeutics on Nov. 19 at an average price of $474.58 for about $1.898M, leaving her with 130 shares—a 96.85% reduction in her ownership, disclosed in an SEC filing.
- Q3 results showed an EPS beat of $7.16 vs. $6.89 consensus while revenue was $799.5M (slightly below estimates) but up 6.8% year‑over‑year; the company reported a 40.65% net margin and 18.83% ROE.
- Wall Street sentiment is generally positive with a consensus rating of "Moderate Buy" and an average price target of $505, while several firms have raised targets (e.g., RBC $587, Jefferies $575); the stock trades near $475 with a market cap of about $20.4B and a P/E around 18.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $474.58, for a total value of $1,898,320.00. Following the transaction, the chief executive officer owned 130 shares of the company's stock, valued at approximately $61,695.40. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Trading Down 0.4%
UTHR stock opened at $474.72 on Friday. The business's fifty day moving average price is $438.38 and its 200 day moving average price is $354.25. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $485.32. The company has a market capitalization of $20.44 billion, a PE ratio of 17.99, a P/E/G ratio of 4.96 and a beta of 0.77.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $6.39 EPS. Research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on UTHR shares. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a "buy" rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday. Wells Fargo & Company lifted their target price on United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a report on Thursday, October 30th. Cantor Fitzgerald upped their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of United Therapeutics in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $505.00.
Read Our Latest Research Report on United Therapeutics
Institutional Trading of United Therapeutics
Institutional investors have recently bought and sold shares of the business. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $29,000. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. SVB Wealth LLC purchased a new position in United Therapeutics in the first quarter valued at approximately $32,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 49 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
